Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In Thrombosis
Thrombosis for May/June 2017
FDA Approves New Treatment for VTE in Acutely Ill, Portola news release; 2017 Jun 23
Taller Height’s Role in Venous Thromboembolism, J Thromb Haemost; ePub 2017 Jun 6; Roetker, et al
Developing a Diagnostic Algorithm for HIT, J Thromb Haemost; ePub 2017 May 11, Husseinzadeh, et al
Predicting VTE Risk in Hospitalized Cancer Patients , Am J Hematol; ePub 2017 May 2; Patell, et al
Consider This Model to Estimate VTE Prophylaxis Risk, J Thromb Haemost; ePub 2017 May 3; Le, et al
Thrombosis for March/April 2017
Rivaroxaban or Aspirin for Extended VTE Treatment, N Engl J Med; 2017 Mar 30; Weitz, Lensing, et al
Thrombosis for January/February 2017
VTE Prophylaxis Options Evaluated , J Thromb Haemost; ePub 2017 Jan 19; Kapoor, et al
Tissue Factor as a Predictor of Recurrent VTE, J Clin Oncol; ePub 2016 Dec 28; Khorana, et al
Hormone and Hemostatic Factor Levels Evaluated, J Thromb Haemost; ePub 2017 Jan 8; Harrington, et al
Thrombosis for November/December 2016
Stroke Risk Biomarkers and Stroke Symptoms Assessed, J Clin Oncol; ePub 2016 Dec 9; Landry, et al
Novel Risk Marker for Venous Thromboembolism? , J Thromb Haemost; ePub 2016 Nov 8; Kubota, et al
Thrombosis for May/June 2016
Genetic Risk for Thrombosis in Thrombocythemia, Am J Hematol; 2016 May; Elala, Lasho, et al